COMPARISON OF MONOTHERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST VERSUS COMBINATION THERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST PLUS A LONG-ACTING BETA2-AGONIST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

被引：0
|
作者：
Yosuke, Tanaka [1 ]
Mitsunori, Hino [1 ]
Naomi, Onda [1 ]
Hiroyuki, Takoi [1 ]
Seiji, Kosaihira [1 ]
Norihisa, Motohashi [1 ]
Akihiko, Gemma [1 ]
机构：
[1] Chiba Hokusoh Hosp, Resp Dis Ctr, Nippon Med Sch, Chiba, Japan
来源：
RESPIROLOGY | 2014年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P-F-073
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [41] Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
    Welsh, Emma J.
    Cates, Christopher J.
    Poole, Phillippa
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (05):
  • [42] Characteristics and treatment pathways of patients with COPD receiving a long-acting muscarinic antagonist/long-acting β2-agonist (LABA/LAMA) in the UK
    Requena, Gema
    Banks, Victoria
    Czira, Alexandrosz
    Wood, Robert
    Tritton, Theo
    Ha, Eunmi
    Wild, Rosie
    Compton, Chris
    Ismaila, Afisi
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [43] A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD
    Sion K.Y.J.
    Huisman E.L.
    Punekar Y.S.
    Naya I.
    Ismaila A.S.
    Pulmonary Therapy, 2017, 3 (2) : 297 - 316
  • [44] ADHERENCE TO CURRENT GUIDELINES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SUBJECTS TREATED WITH COMBINATION OF LONG-ACTING B2-AGONIST (LABA), LONG-ACTING MUSCARINIC ANTAGONIST (LAMA) OR INHALED CORTICOSTEROIDS (ICS)
    Asche, C.
    Leader, S.
    Plauschinat, C.
    Raparla, S.
    Ye, X.
    Yan, M.
    Young, D.
    VALUE IN HEALTH, 2011, 14 (07) : A492 - A492
  • [45] Long-acting muscarinic antagonists
    Melani, Andrea S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2015, 8 (04) : 479 - 501
  • [46] Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting 132 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting 132 Agonists Plus Inhaled Corticosteroids
    Liao, Pei-An
    Pan, Sheng-Wei
    Chen, Chun-Yu
    Deng, Chung-Yeh
    Dong, Yaa-Hui
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2023, 18 : 553 - 563
  • [47] Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting I32-Agonist Dual Therapy in a Primary Care Setting in England
    Requena, Gema
    Banks, Victoria
    Czira, Alexandrosz
    Wood, Robert
    Tritton, Theo
    Wild, Rosie
    Compton, Chris
    Duarte, Maria
    Ismaila, Afisi S.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 1781 - 1795
  • [48] Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease
    Sarac, Pinar
    Sayiner, Abdullah
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [49] Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients
    Decramer, Marc
    Maltais, Francois
    Feldman, Gregory
    Brooks, Jean
    Harris, Stephanie
    Mehta, Rashmi
    Crater, Glenn
    RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 2013, 185 (02) : 393 - 399
  • [50] Revefenacin, a once-daily, long-acting muscarinic antagonist, or nebulized maintenance therapy in patients with chronic obstructive pulmonary disease
    Hvisdas, Christopher
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2021, 78 (13) : 1184 - 1194
12345